<DOC>
	<DOCNO>NCT00004917</DOCNO>
	<brief_summary>RATIONALE : Radiation therapy use high-energy x-rays damage tumor cell . Epoetin alfa may stimulate red blood cell production treat anemia patient head neck cancer . It yet know whether receive radiation therapy epoetin alfa effective radiation therapy alone treat anemic patient head neck cancer . PURPOSE : Randomized phase III trial compare effectiveness radiation therapy without epoetin alfa treat anemic patient head neck cancer .</brief_summary>
	<brief_title>Radiation Therapy With Without Epoetin Alfa Treating Anemic Patients With Head Neck Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine whether epoetin alfa give definitive radiotherapy chemoradiotherapy improve local-regional control rate anemic patient squamous cell carcinoma head neck . Secondary - Determine whether drug improves survival patient population . - Identify pattern first failure patient . - Determine whether significant increase hemoglobin level baseline value value 28 day start epoetin alfa patient . - Assess toxicity regimen patient . OUTLINE : This randomize study . Patients stratify accord stage ( I/II vs III/IV without chemotherapy v III/IV chemotherapy ) , pretreatment hemoglobin level ( 9.0 less 11.5 g/dL v 11.5 13.5 g/dL ) , gender . Patients randomize one two treatment arm . - Arm I : Patients stage I II disease undergo radiotherapy daily 6-7 week . Patients stage III IV disease undergo radiotherapy daily 3.5 week twice daily ( 6 hour apart ) 2.5 week total 6 week . - Arm II : Patients undergo radiotherapy arm I . Beginning 7-10 day radiotherapy , patient receive epoetin alfa subcutaneously weekly end radiotherapy . Patients stage III/IV disease may receive concurrent cisplatin IV 1-2 hour day 1 22 radiotherapy . Patients follow every 3 month 2 year , every 6 month 3 year , annually thereafter . PROJECTED ACCRUAL : A total 372 patient ( 186 per arm ) accrue study within 3.5 year .</detailed_description>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm invasive squamous cell carcinoma head neck , include carcinoma arise oral cavity , oropharynx , larynx , hypopharynx Stage IIV disease No distant metastases No carcinoma nasopharynx , nasal cavity/paranasal sinus , salivary glands No carcinoma situ without identifiable invasive component Plan radiotherapy continuous course Prior surgical exploration gross residual disease remain allow Prior neck dissection without biopsy primary tumor , radical surgery primary tumor , allow Anemia , define hemoglobin great 13.5 g/dL male great 12.5 g/dL female ( transfusion prior study allow ) No severe anemia ( i.e. , hemoglobin le 9.0 g/dL ) No anemia confirm due cause chronic disease ( e.g. , iron deficiency anemia ) Not enter RTOG head neck protocols PATIENT CHARACTERISTICS : Age : 18 Performance status : Zubrod 02 Life expectancy : Not specify Hematopoietic : See Disease Characteristics Stage III/IV patient receive concurrent cisplatin : Absolute neutrophil count least 2,000/mm^3 Platelet count least 100,000/mm^3 Hepatic : Not specify Renal : Stage III/IV patient receive concurrent cisplatin : Creatinine great 1.5 mg/dL Creatinine clearance least 50 mL/min Cardiovascular : No malignant poorly control hypertension ( e.g. , symptomatic hypertension diastolic blood pressure 100 mm Hg great despite antihypertensive medication ) No unstable angina poorly control cardiac disease Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception If stage III IV disease present , willing come twice daily radiotherapy last 2.5 week therapy No active infection require IV antibiotic No unexplained fever No AIDS history congenital acquire immunodeficiency No malignancy within past 3 year except carcinoma situ nonmelanomatous skin cancer No know hypersensitivity mammalian cellderived product human albumin No acute/subacute illness would make need transfusion likely PRIOR CONCURRENT THERAPY : Biologic therapy : At least 4 week since prior cytokine therapy ( e.g. , filgrastim [ GCSF ] , interleukins , interferon ) No prior epoetin alfa No concurrent cytokine therapy Chemotherapy : No prior chemotherapy Concurrent cisplatin , paclitaxel/cisplatin , paclitaxel/carboplatin patient stage III/IV disease allow Endocrine therapy : Not specify Radiotherapy : See Disease Characteristics No prior radiotherapy head neck Surgery : See Disease Characteristics Other : No concurrent amifostine No concurrent transfusion</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>stage I squamous cell carcinoma lip oral cavity</keyword>
	<keyword>stage II squamous cell carcinoma lip oral cavity</keyword>
	<keyword>stage III squamous cell carcinoma lip oral cavity</keyword>
	<keyword>stage IV squamous cell carcinoma lip oral cavity</keyword>
	<keyword>stage I squamous cell carcinoma oropharynx</keyword>
	<keyword>stage II squamous cell carcinoma oropharynx</keyword>
	<keyword>stage III squamous cell carcinoma oropharynx</keyword>
	<keyword>stage IV squamous cell carcinoma oropharynx</keyword>
	<keyword>stage I squamous cell carcinoma hypopharynx</keyword>
	<keyword>stage II squamous cell carcinoma hypopharynx</keyword>
	<keyword>stage III squamous cell carcinoma hypopharynx</keyword>
	<keyword>stage IV squamous cell carcinoma hypopharynx</keyword>
	<keyword>stage I squamous cell carcinoma larynx</keyword>
	<keyword>stage II squamous cell carcinoma larynx</keyword>
	<keyword>stage III squamous cell carcinoma larynx</keyword>
	<keyword>stage IV squamous cell carcinoma larynx</keyword>
	<keyword>anemia</keyword>
</DOC>